Contact Us
Plans and Services Health and Wellness About Wellmark Member Employer Producer Provider
Home Provider Medical Policies and Authorizations Medical Policies A - Z

» Working with
» News
» BlueCard®
» Claims and Payment
» Medical Policies and Authorizations
» Health Management
» Medical, Dental, and Pharmacy
» Credentialing and Contracting
» Quality and Transparency
» Communications and Resources
» Health Care Reform for Providers
printer friendly Printer-Friendly Page

Dermatologic Applications of Photodynamic Therapy

» Summary» Procedure Codes
» Description» Selected References
» Prior Approval» Policy History
» Policy

Medical Policy: 02.01.16 
Original Effective Date: January 2002 
Reviewed: March 2015 
Revised: March 2015 

Benefit Application
Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This medical policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

This Medical Policy document describes the status of medical technology at the time the document was developed. Since that time, new technology may have emerged or new medical literature may have been published. This Medical Policy will be reviewed regularly and be updated as scientific and medical literature becomes available.


Photodynamic therapy (PDT) refers to light activation of a photosensitizer to generate highly reactive intermediaries, which ultimately cause tissue injury and necrosis. Photosensitizing agents, administered orally or intravenously, have been used in non-dermatologic applications and are being proposed for use with dermatologic conditions such as actinic keratoses and non-melanoma skin cancers.


Photodynamic therapy typically involves two office visits. One to apply the topical photosensitizing agent and a second visit to the expose the patient to the light source. The photoactivation of the drug creates a cytotoxic reaction within the cells that destroys dysplastic lesions. The cytotoxic effect is dependent on light and oxygen.
Photodynamic protocols typically involve two treatments spaced a week apart, more then one treatment series may be required.   

Two common photosensitizing agents are 5-aminolevulinac acid (5-ALA) and its methyl ester methyl aminolevulinate (MAL). When applied topically they pass through the abnormal keratin overlying the lesion and accumulate preferentially in dysplastic cells. 5-ALA and MAL are metabolized by the underlying cells to photosensitizing concentrations of porphyrins. Subsequent exposure to photoactivation (maximum absorption at 404-420 nm and 635 nm, respectively) generates reactive oxygen species that are cytotoxic, ultimately destroying the lesion. PDT can cause erythema, burning, and pain. Healing occurs within 10 to 14 days, with generally acceptable cosmetic results. PDT with topical ALA has been investigated primarily as a treatment of actinic keratoses. It has also been investigated as a treatment of other superficial dermatologic lesions such as Bowen's disease, acne vulgaris, mycoses, hidradenitis suppurativa, and superficial and nodular basal cell carcinoma. Potential cosmetic indications include skin rejuvenation and hair removal.


Actinic keratosis is the most common premalignant skin condition.  The rough scaly plaques are the direct results of damage from ultraviolet light and other carcinogenic exposures.  It is commonly seen on the sun-exposed skin of elderly patients with fair complexions. The available treatments for actinic keratoses can generally be divided into surgical and non-surgical methods. Surgical treatments used to treat one or a small number of dispersed individual lesions include excision, curettage (either alone or combined with electrodessication), and laser surgery. Non-surgical treatments include cryotherapy, topical chemotherapy (5-fluorouracil [5-FU] or masoprocol creams), chemexfoliation (also known as chemical peels), and dermabrasion. Topical treatments are generally used in patients with multiple lesions and the involvement of extensive areas of the skin. Under some circumstances, combinations of different treatment methods may be used.


Non-melanoma skin cancers are the most common malignancies in the Caucasian population. Basal cell carcinoma (BCC) is most often found in light-skinned individuals and is the most common of the cutaneous malignancies. Although the tumors rarely metastasize, they can be locally invasive if left untreated, leading to significant local destruction and disfigurement. The most prevalent forms of BCC are nodular BCC and superficial BCC. Bowen's disease is a squamous cell carcinoma (SCC) in situ with the potential for significant lateral spread. Metastases are rare, with less than 5% of cases advancing to invasive SCC. Lesions may appear on sun-exposed or covered skin. Excision surgery is the preferred treatment for smaller non-melanoma skin lesions and those not in problematic areas, such as the face and digits. Other established treatments include topical 5-fuorouracil, imiquimod, and cryotherapy. Poor cosmesis resulting from surgical procedures and skin irritation induced by topical agents can be significant problems.


The evidence to date for photodynamic therapy (PDT) suggests that net health outcomes is better with surgery than with PDT for treating basal cell carcinoma (BCC). For superficial BCC, the evidence is sufficient to conclude that PDT has similar efficacy to cryotherapy. In addition, there is evidence from the randomized controlled trials that PDT is an effective treatment for selected patients with actinic keratosis of the face and scalp compared to placebo or cryotherapy. There is insufficient evidence that PDT improves the net health outcome for nodular BCC and other dermatologic conditions compared to accepted treatments. Thus, PDT may be considered medically necessary for treating selected patients with non-hyperkeratotic actinic keratosis of the face and scalp, low risk superficial or nodular (less than 2mm in depth) BCC, and Bowen's disease (squamous cell carcinoma in-situ) and is considered investigational for all other dermatologic indications.


Practice Guidelines and Position Statements


National Comprehensive Cancer Network (NCCN)
Version 1.2015 Basal Cell and Squamous Cell Skin Cancers


Principles of Treatment for Basal Cell Skin Cancers

• In patients with low risk, superficial basal cell skin cancer, where surgery or radiation is contraindicated or impractical, topical therapies such as 5-fluorouracil, imiquimod, photodynamic therapy (e.g. aminal levulinic acid (ALA), porfimer sodium) or vigorous cryotherapy may be considered,e ven thought the cure rate may be lower.


National Comprehensive Cancer Network (NCCN)

Version 1.2012 Squamous Cell Skin Cancer

Principles of Treatment for Squamous Cell Skin Cancer

• In patients with squamous cell carcinoma in situ (Bowen’s disease) that is low risk, alternative therapies such as 5-flurouracil, imiquimod, photodynamic therapy (e.g. amino levulinic acid (ALA), profimer sodium) or vigorous cryotherapy may be considered even though cure rate may be lower.  

International Society for Photodynamic Therapy in Dermatology
The International Society for Photodynamic Therapy in Dermatology published consensus based guidelines on the use of photodynamic therapy (PDT) for non-melanoma skin cancer in 2005.

  • Actinic Keratosis (AK): As PDT with either ALA or MAL is highly effective and offers excellent cosmetic outcome, it should be considered as a first-line therapy for AK (Rating: AI); MAL-PDT has a superior cosmetic outcome compared to cryotherapy (Rating: AI)
  • Bowen’s Disease (BD):  Topical PDT is effective in BD, achieving good cosmesis, and is at least as effective as cryotherapy or 5-fluorouacil, but with fewer adverse events; topical PDT should be considered as a first-line therapy for BD (Rating AI). 
  • Squamous Cell Carcinoma (SCC): There is insufficient evidence to support the routine use of topical PDT for SCC (Rating: CIIiii).
  • Superficial Basal Cell Carcinoma (sBBC): PDT is an effective and reliable treatment option for SBCC that offers excellent cosmetic outcomes (Rating: AI); PDT offers an advantage in treatment of large, extensive and multiple lesions (Rating AI); MAL-PDT has demonstrated long-term efficacy, with 5 year follow up data (Rating: AI).
  • Nodular Basal Cell Carcinoma (nBBC): MAL-PDT is an effective and reliable treatment option for nBBC less than 2 mm in depth with the advantage of good cosmetic outcome (Rating: AI); MAL-PDT has demonstrated long-term efficacy with 5 year follow up data. (Rating: AI).

Regulatory Status

Levulan® Kerastick&trade  is a topical preparation of ALA used in conjunction with illumination with the BLU-U&trade Blue Light Photodynamic Therapy Illuminator, a blue light source. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of non-hyperkeratotic actinic keratoses of the face and scalp.  The product is applied in the physicians office.


Another variant of PDT for skin lesions is Metvixia® and the Aktilite CL 128 lamp, each of which received FDA approval in 2004. Metvixia consists of the topical application of methyl aminolevulinate (MAL) followed by exposure with the Altilite CL 128 lamp, a red light source. Metvixia is indicated for the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunoincompetent patients when used in conjunction with lesion preparation (sharp debridement) in the physician's office when other therapies are unacceptable or considered medically less appropriate.


A 5-aminoleveulinic acid patch technology (5-ALA Patch) is available outside of the U.S. through an agreement between Intendis (part of Bayer HealthCare) and Photonamic GmbH and Co. KG. The 5-ALA patch is not approved by the FDA.  


Prior Approval: 


Not applicable



Photodynamic therapy may be considered medically necessaryas a treatment of:

  • Non-hyperkeratotic actinic keratoses of the face and scalp.
  • Low risk superficial or nodular (less than 2 mm in depth) basal cell skin cancer only when surgery and radiation are contraindicated.
  • Bowen's disease (squamous cell carcinoma in situ) only when surgery and radiation are contraindicated.

Photodynamic therapy is considered investigational for other dermatologic applications, including, but not limited to the following:

  • Acne vulgaris,
  • High risk basal cell carcinomas,
  • Hidradenitis suppurativa, 
  • Mycoses
  • Warts

No high-quality comparative studies have evaluated photodynamic therapy for acne or other dermatologic conditions. The evidence is insufficient to show that photodynamic therapy improves net health outcomes for these conditions and therefore is considered investigational.


Procedure Codes and Billing Guidelines: 

  • To report provider services, use appropriate CPT* codes, Modifiers, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or diagnosis codes.
  • 96567 photodynamic therapy for actinic keratosis. 
  • J7308 5-ALA (Levulan® Kerastick®) for topical administration.
  • J7309 Methyl aminolevulinate (MAL) for topical administration, 16.8%, 1 gram


Selected References: 

  • Feldman SR, Fleischer AB, Williford PM, Jorizzo JL. Destructive procedures are the standard of care for the treatment of actinic keratoses. The Journal of American Academy of Dermatology1999;40:43-47
  • Leber K, Perron VD, Sinni-McKeehen B. Common Skin Cancers in the United States: A Practical Guide for Diagnosis and Treatment. Nurse Practitioner Forum 1999;10 (2): 106-112
  • Jeffes III EWB, Tang EH. Actinic Keratosis. The Journal of Clinical Dermatology2000 May-June;1(3):167-179
  • Ormrod D, Jarvis B. Topical Aminolevulinic Acid HCl Photodynamic Therapy. The Journal of Clinical Dermatology2000 March-April;1 (2): 133-139
  • Barnaby JWJ, Styles AR, Cockerell CJ. Actinic Keratoses. Drugs and Aging 1997 September;11(3)186-205
  • ECRI Institute. Photodynamic Therapy with Aminolevulinic Acid for Treatment of Actinic Keratosis and Other Skin Lesions. Plymouth Meeting (PA): ECRI Institute; 2008 August 6. 17 p. [ECRI hotline response].
  • Morton CA, McKenna KE, Rhodes LE; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: update. Br J Dermatol. 2008 Dec;159(6):1245-66.
  • Orringer JS, Sachs DL, Bailey E et al. Photodynamic therapy for acne vulgaris: a randomized, controlled, split-face clinical trial of topical aminolevulinic acid and pulsed dye laser therapy. J Cosmet Dermatol. 2010 Mar;9(1):28-34.
  • Foley P, Freeman M, Menter A et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol. 2009 Nov;48(11):1236-45.
  • Fantini F, Greco A, Del Giovane C et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol. 2011 Aug;25(8):896-901. doi: 10.1111/j.146803083.2010.03877.x. Epub 2010 Nov 4.
  • Fayter D, Corbett M, Heirs M et al. A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesphagus and cancers of the biliary tract, brain, head and neck, lung, oesphagus and skin. Health Technol Assess. 2010 Jul;14(37):1-288.
  • Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and non-randomized trials. Br J Dermatol. 2012 May 21. [Epub ahead of print]
  • Hadley J, Tristani-Firouzi P, Hull C, Florell S, et al. Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses. Dermatol Surg. 2012 May;38(5):722-7.
  • Serra-Guillen C, Nagore E, Hueso L, Traves V, et al. A randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomes. J Am Acad Dermatol. 2012 Apr;66(4):e131-7.
  • Medscape Reference Drugs, Diseases and Procedures. Photodynamic Therapy for the Dermatologists. Jaggi Rao, M.D. et al. Updated March 3, 2014.
  • National Comprehensive Cancer Network (NCCN) Version 2.2014 Basal and Squamous Cell Skin Cancers.
  • UpToDate. Treatment of Actinic Keratosis. Joseph Jorizzo M.D.. Topic last updated June 21, 2013.
  • UpToDate. Treatment and Prognosis of Basal Cell Carcinoma. Timothy K. Chartier, M.D., Sumaria Z. Aasi, M.D.Topic last updated March 14, 2014.
  • UpToDate. Treatment and Prognosis of Cutaneous Squamous Cell Carcinoma. Timothy K. Chartier, M.D., Sumaira Z. Aasi, M.D. Topic last updated January 22, 2014.
  • UpToDate. Nonablative Skin Resurfacing for Skin Rejuvination. Macrene Alexiades-Armenakas, M.D., PhD. Topic last updated January 15, 2013.
  • CMS National Coverage Determination (NCD) for Treatment of Actinic Keratosis (250.4). Also available at
  • National Comprehensive Cancer Network (NCCN) Basal Cell Skin Cancer, Version 1.2015. Also available at
  • National Comprehensive Cancer Network (NCCN) Squamous Cell Skin Cancer, Version 1.2015. Also available at
  • American Academy of Dermatology: Actinic Keratosis: Diagnosis, Treatment and Outcome; Basal Cell Carcinoma: Diagnosis, Treatment and Outcome; Hidradenitis Suppurativa: Diagnosis, Treatment and Outcome; Warts: Diagnosis, Treatment and Outcome. Also available at
  • National Guideline Clearinghouse: British Association of Dermatologists’ Guidelines for the Management of Squamous Cell Carcinoma In Situ (Bowen’s Disease) 2014. Also available at
  • Braathen LR, Szeimies RM, Basset-Seguin N, et. al. 2005 Consensus Based Guidelines on the use of PDT for non-melanoma skin cancer, International Society for Photodynamic Therapy in Dermatology. J Am Acad Dermatol. Jan 2007;56(1):125-143.
  • UpToDate. Treatment of Actinic Keratosis. Joseph Jorizzo, M.D., Topic last updated October 1, 2014. Also available at
  • UpToDate. Treatment and Prognosis of Basal Cell Carcinoma, Timothy K. Chartier, M.D., Sumaira Z. Aasi, M.D., Topic last updated September 23, 2014
  • UpToDate. Treatment and Prognosis of Cutaneous Squamous Cell Carcinoma, Timothy Chartier, M.D., Sumaira Z. Aasi, M.D., Topic last updated November 19, 2014. Also available at


Policy History: 


Date                                        Reason                               Action

August 2011                           Annual review                     Policy renewed

June 2012                              Annual review                     Policy renewed

May 2013                              Annual review                     Policy renewed

April 2014                              Annual review                     Policy renewed

March 2015                           Annual review                     Policy revised


Wellmark medical policies address the complex issue of technology assessment of new and emerging treatments, devices, drugs, etc.   They are developed to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. Wellmark medical policies contain only a partial, general description of plan or program benefits and do not constitute a contract. Wellmark does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Wellmark or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. Our medical policies may be updated and therefore are subject to change without notice.

*Current Procedural Terminology © 2012 American Medical Association. All Rights Reserved.

Contact Information
New information or technology that would be relevant for Wellmark to consider when this policy is next reviewed may be submitted to:
  Wellmark Blue Cross and Blue Shield
  Medical Policy Analyst
  P.O. Box 9232
  Des Moines, IA 50306-9232
FacebookTwitterInstagrampinterestLinked InYou Tube